润肤浴添加剂治疗儿童湿疹的临床与成本效果:BATHE多中心实用随机对照试验
BATHE试验在96家全科诊所纳入483名1–11岁符合英国特应性皮炎诊断标准的儿童,随机分为常规使用润肤浴添加剂组与不使用浴添加剂组,均继续标准湿疹管理。主要结局为16周内每周POEM评分,两组无统计学显著差异,校正后无浴添加剂组POEM仅高0.41分(95%CI -0.27至1.10),低于POEM最小临床重要差异3分,次要结局、经济学结局及不良事件均无差异。
要点
- 在标准湿疹管理中加入润肤浴添加剂未显示临床获益。
- 16周POEM评分组间差异0.41分(95%CI -0.27至1.10),低于最小临床重要差异3分。
- 两组在次要结局、经济结局及不良事件方面均无差异。
核心结论
- 本试验未发现将润肤浴添加剂纳入儿童湿疹标准管理具有临床获益的证据。
研究设计与样本
- 实用随机开放标签优效性试验,两组平行设计,在威尔士及英格兰西部和南部96家全科诊所开展。
- 纳入483名1至11岁符合英国特应性皮炎诊断标准的儿童,排除湿疹极轻及每周洗澡少于1次的儿童。
- 干预组由常规临床团队处方润肤浴添加剂并定期使用12个月,对照组要求12个月不使用浴添加剂,两组均继续标准湿疹管理包括留涂润肤剂。
主要发现
- 16周期间平均POEM评分:浴添加剂组7.5(SD 6.0),无浴添加剂组8.4(SD 6.0)。
- 校正基线严重度、混杂因素及中心与个体内聚集后,无浴添加剂组POEM评分比浴添加剂组高0.41分(95%CI -0.27至1.10),低于POEM最小临床重要差异3分。
- 两组在次要结局、经济学结局或不良事件方面均无差异。
关键数值与推荐
- 主要结局为患者导向湿疹测量(POEM,0–7轻度、8–16中度、17–28重度)在16周内每周评估。
- 基线平均POEM评分:浴添加剂组9.5(SD 5.7),无浴添加剂组10.1(SD 5.8)。
- 96%(461/482)参与者完成至少一次基线后POEM并纳入分析,77%(370/482)完成主要结局超过80%时间点的问卷。
临床怎么用
- 临床不应将润肤浴添加剂作为儿童湿疹标准管理的常规推荐。
- 继续标准湿疹管理,包括留涂润肤剂和肥皂替代品。
- 需进一步研究留涂润肤剂和肥皂替代品的最佳方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the clinical effectiveness and cost effectiveness of including emollient bath additives in the management of eczema in children. DESIGN: Pragmatic randomised open label superiority trial with two parallel groups. SETTING: 96 general practices in Wales and western and southern England. PARTICIPANTS: 483 children aged 1 to 11 years, fulfilling UK diagnostic criteria for atopic dermatitis. Children with very mild eczema and children who bathed less than once weekly were excluded. INTERVENTIONS: Participants in the intervention group were prescribed emollient bath additives by their usual clinical team to be used regularly for 12 months. The control group were asked to use no bath additives for 12 months. Both groups continued with standard eczema management, including leave-on emollients, and caregivers were given standardised advice on how to wash participants. MAIN OUTCOME MEASURES: The primary outcome was eczema control measured by the patient oriented eczema measure (POEM, scores 0-7 mild, 8-16 moderate, 17-28 severe) weekly for 16 weeks. Secondary outcomes were eczema severity over one year (monthly POEM score from baseline to 52 weeks), number of eczema exacerbations resulting in primary healthcare consultation, disease specific quality of life (dermatitis family impact), generic quality of life (child health utility-9D), utilisation of resources, and type and quantity of topical corticosteroid or topical calcineurin inhibitors prescribed. RESULTS: 483 children were randomised and one child was withdrawn, leaving 482 children in the trial: 51% were girls (244/482), 84% were of white ethnicity (447/470), and the mean age was 5 years. 96% (461/482) of participants completed at least one post-baseline POEM, so were included in the analysis, and 77% (370/482) completed questionnaires for more than 80% of the time points for the primary outcome (12/16 weekly questionnaires to 16 weeks). The mean baseline POEM score was 9.5 (SD 5.7) in the bath additives group and 10.1 (SD 5.8) in the no bath additives group. The mean POEM score over the 16 week period was 7.5 (SD. 6.0) in the bath additives group and 8.4 (SD 6.0) in the no bath additives group. No statistically significant difference was found in weekly POEM scores between groups over 16 weeks. After controlling for baseline severity and confounders (ethnicity, topical corticosteroid use, soap substitute use) and allowing for clustering of participants within centres and responses within participants over time, POEM scores in the no bath additives group were 0.41 points higher than in the bath additives group (95% confidence interval -0.27 to 1.10), below the published minimal clinically important difference for POEM of 3 points. The groups did not differ in secondary outcomes, economic outcomes, or adverse effects. CONCLUSIONS: This trial found no evidence of clinical benefit from including emollient bath additives in the standard management of eczema in children. Further research is needed into optimal regimens for leave-on emollient and soap substitutes. TRIAL REGISTRATION: Current Controlled Trials ISRCTN84102309.
引用
- Santer M, Ridd MJ, Francis NA, et al. Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness. BMJ. 2018. PMID: 29724749. doi:10.1136/bmj.k1332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。